Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 204 participants.

Also called NCT07041281

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 204 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07041281
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07041281. Randomized; quadruple masking; primary purpose treatment. Start 2025-10-16 (actual); primary completion 2027-12-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories
Acronym
IMPACT-HT
Condition
Preeclampsia
Condition
Gestational Hypertension
Intervention (Drug)
spironolactone 25 mg orally once daily
Intervention (Drug)
Placebo tablet to match spironolactone
Lead sponsor
Massachusetts General Hospital (class: other)
Collaborator
Brigham and Women's Hospital (class: other)
Collaborator
University of Pittsburgh Medical Center (class: other)

Record details

Record id
cardio:ct-nct07041281
Content hash
fa9a91aa24fb75f305af0d30f6f17034be3269c1f26f2c15c143ad169a8aa99c